MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

June 2012


Part D Changes for 2013 Will Put Pressure on P&T Committees

Drug Utilization Reviews and Medication Therapy Management Programs Under the Gun

Medicare wants to improve its drug program’s effectiveness, reduce costs, and increase its oversight of formulary policies and prescribing, especially for opioids.
Stephen Barlas

Health Care and Law

Policies and Procedures

Enhancing Pharmacy Practice and Limiting Risk

P&T committee members, many of whom are not pharmacists, must be able to understand their organization’s P&Ps in order to minimize patient injury and avoid legal land mines.
James O’Donnell, PharmD, MS; and F. Randy Vogenberg, RPh, PhD

Management of Urinary Incontinence

Almost 10 million people in the U.S., many of them elderly, have various forms of this troubling condition. The types and causes of, risk factors for, and physiology of urinary incontinence, as well as conservative and pharmacological treatments, are discussed.
George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD

Meeting Highlights

47th European Association for the Study of the Liver (EASL)/The International Liver Conference

Topics include interferon-free therapies, pegylated interferon lambda-1a, and boceprevir (Victrelis) for the treatment of hepatitis C virus infection.
Walter Alexander

Meeting Highlights

American Academy of Dermatology

Sessions included therapies for psoriasis, acne, nail fungus, and superficial skin cancers.
Peter Sonnenreich, MA


Medication Errors

Actively Caring for the Safety of Patients

Overcoming Bystander Apathy

Eliminating bystander apathy requires active participation.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

FDA to Reassess Policies on Unsolicited Requests for Off-Label Information

Differentiating ‘Scientific Exchange’ From ‘Promotion’ Is Complicated

Will the FDA ease restrictions on disseminating unsolicited requests for off-label information?
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Florbetapir F18 (Amyvid) dye for detecting plaques in Alzheimer’s disease; avanafil (Stendra) for erectile dysfunction; and peginesatide injection (Omontys) for anemia in patients with chronic kidney disease
Marvin M. Goldenberg, PhD, RPh, MS